NEW YORK — Micronbrane Medical said Monday that it has signed on Europa Biosite as a European distributor of its metagenomic next-generation sequencing-based pathogen identification products.
The deal includes Micronbrane's PaRTI-Seq (Pathogen Real-Time Identification by Sequencing) assay and related technologies, which uses NGS to identify pathogens and other microbes within 24 hours. According to the Taiwanese company, the assay has been validated with a range of liquid biopsy samples and is being used clinically for laboratory-developed tests.
About two years ago, Micronbrane raised $4.5 million in Series A funding.